Skip to Content
Biometric Research Program (BRP)

Dr. Jared C. Foster

Mathematical Statistician, Biostatistics Branch


Research Interests

My primary interest is in the design, monitoring and analysis of oncology clinical trials, and I am particularly interested in phase II trials. In terms of statistical methodology, I am interested in problems relating to prediction, subgroup identification and variable selection, and much of my research has been in the area of personalized medicine.

CV (Updated Feb., 2021)


Selected Peer Reviewed Papers:

Foster, JC, Taylor, JMG and Ruberg, SJ (2011), Subgroup identification from randomized clinical trial data, Statistics in Medicine, 30(24):2867-2880

Foster, JC, Taylor, JMG and Nan, B (2013), Variable selection in monotone single- index models via the adaptive LASSO, Statistics in Medicine, 32(22):3944-54

Mason, H, DeRubeis, MB, Foster, JC, Taylor, JMG, Friese, C and Worden, FP (2013), Outcomes Evaluation of a Weekly Nurse Practitioner-Managed Symptom Management Clinic for Patients with Head and Neck Cancer Treated with Chemoradiotherapy, Oncology Nursing Forum, 40(6):581-6

Taylor, JMG, Cheng, W, and Foster, JC (2014), Reader Reaction to "A robust method for estimating optimal treatment regimes" by Zhang et al (2012), Biometrics, doi: 10.1111/biom.12228

Foster JC, Taylor JM, Kaciroti N, Nan B. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data. Biostatistics. 2015 Apr; 16(2):368-82. Epub 2014 Nov 13. PMID: 25398774 DOI: 10.1093/biostatistics/kxu049

Foster JC, Nan B, Shen L, Kaciroti N, Taylor JMG. Permutation Testing for Treatment-Covariate Interactions and Subgroup Identification. Statistics in Bioscience. 2015. DOI: 10.1007/s12561-015-9125-9

Foster JC, Liu D, Albert PS, Liu A. Identifying Subgroups of Enhanced Predictive Accuracy from Longitudinal Biomarker Data Using Tree-Based Approaches: Applications to Fetal Growth. Journal of the Royal Statistical Society: Series A (Statistics in Society).2016; DOI: 10.1111/rssa.12182

Freedman RA, Foster JC, Seisler DK, Lafky JM, Muss HB, Cohen HJ, Mandelblatt J, Winer EP, Hudis CA, Partridge AH, Carey LA, Cirrincione C, Moreno-Aspitia A, Kimmick G, Jatoi A, Hurria A. (2016), Accrual of Older Breast Cancer Patients to Alliance Systemic Therapy Trials over Time: Protocol A151527. Journal of Clinical Oncology

Himelstein A, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of longer interval dosing vs. standard dosing of zoledronic acid on skeletal events among patients with bone metastasis: a randomized clinical trial. Journal of the American Medical Association 2017, 317(1):48-58. doi:10.1001/jama.2016.19425

Foster JC, Freidlin B, Kunos CA, Korn EL: Single-Arm Phase II Trials of Combination Therapies: The CTEP Experience 2008-2017, Journal of the National Cancer Institute, djz193, https://doi.org/10.1093/jnci/djz193, 2019

Foster JC, Freidlin B, Korn EL, Smith MA, An Evaluation of the Contribution of Randomized Cancer Clinical Trials Evaluating Agents without Documented Single Agent Activity (Accepted by ESMO Open, 2020)

Reuss JE, Stern D, Foster J, Ramaswami R, Lurain K, Chen H, Streicher H, Kem R, Little RF, Sharon E, Inclusion of people living with HIV in anti-PD(L)1 clinical trials: Results of an NCI-driven initiative to broaden eligibility in cancer clinical trial development (Accepted by JAMA Network Open, 2020)



Dr. Jared Foster

Office Address:
Room 5W638
9609 Medical Center Dr
Rockville, MD 20850

Contact Information:
Tel: (240) 276-6037
Fax: (240) 276-7888
Email:jared.foster@nih.gov